What question did this study set out to answer?

This research aims to investigate the role of circulating plasma cells as biomarkers of aggressive multiple myeloma phenotypes.

August 11, 2026Scientific ReportsOpen Access

Circulating plasma cells (polyclonal and monoclonal) as markers of an aggressive multiple myeloma phenotype

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates circulating plasma cells in multiple myeloma patients, suggesting a link to aggressive disease traits.

This research aims to investigate the role of circulating plasma cells as biomarkers of aggressive multiple myeloma phenotypes.
Analyzed circulating plasma cells (CPCs) in 108 multiple myeloma patients using next generation flow.
Studied the correlation between CPCs in peripheral blood and clinical parameters.
Examined the expression of markers like CD56 and CD138 to assess immunophenotypic heterogeneity.
CPCs were found in 92% of patients, with 77% being monoclonal and 15% polyclonal.
High CPCs correlated significantly with adverse clinical parameters (p < 0.05).
High CPCs patients primarily had KRAS mutations, while low CPCs patients showed NRAS mutations.

Vigliotta et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark